Page last updated: 2024-11-05

iodoform

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6374
CHEMBL ID1451116
CHEBI ID37758
MeSH IDM0055992

Synonyms (67)

Synonym
AKOS009031506
wln: iyii
nsc-26251
carbon triiodide
nci-c04568
iodoform
methane, triiodo-
triiodomethane
nsc26251
chi3
jodoform
CHEBI:37758 ,
75-47-8
NCGC00091389-01
ccris 346
ai3-52396
hsdb 4099
iodoform [jan]
dezinfekt v
trijodmethane [czech]
einecs 200-874-5
jodoform [czech]
nsc 26251
D01910
iodoform (tn)
iodoform (jp17/usp)
iodoform, 99%
NCGC00091389-02
tri-iodomethane
A838427
tris(iodanyl)methane
NCGC00091389-03
cas-75-47-8
tox21_302774
dtxcid40743
NCGC00256394-01
dtxsid4020743 ,
NCGC00259938-01
tox21_202389
tox21_111124
iodoformum
CHEMBL1451116
trijodmethane
kxi2j76489 ,
iodoform [usp:jan]
unii-kxi2j76489
FT-0627266
iodoform [mi]
iodoform [hsdb]
iodoform [usp monograph]
iodoform [inci]
iodoform [who-dd]
iodoformum [hpus]
iodoform [mart.]
S12111
J-650249
mfcd00001069
iodoform, saj first grade
iodoform, purum, >=99.0% (at)
iodoform, puriss., 99.0-100.5%
methyl triiodide
DB13813
Q412393
AS-14199
iodoform (mart.)
triiodo methane
iodoform (usp monograph)

Research Excerpts

Overview

Iodoform gauze packing is an alternative therapy for postoperative parotid fistula.

ExcerptReferenceRelevance
"Iodoform gauze packing is an alternative therapy for postoperative parotid fistula."( Iodoform Gauze Packing is an Alternative Therapy for Postoperative Parotid Fistula.
Hao, X; Lv, K,
)
2.3

Treatment

ExcerptReferenceRelevance
"Treatment with iodoform would be beneficial."( Time Intervals Between Prior Cervical Conization and Posterior Hysterectomy Influence Postoperative Infection in Patients with Cervical Intraepithelial Neoplasia or Cancer.
Liu, S; Tan, W; Xu, W; Yin, X; Zhu, L; Zhu, X, 2018
)
0.82

Toxicity

ExcerptReferenceRelevance
" The second objective of these experiments was to determine the toxic effect of iodoform vapor on rats exposed for 7 h/d for 7 consecutive days."( Subacute inhalation toxicity testing with iodoform vapor.
Kendall, FM; Landin, W; Miller, A; Oberly, R; Sherman, W; Tansy, MF; Werley, M,
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"Fifteen extraction sockets packed with a new drug combination which includes a local anaesthetic (cincain chloride), a local antiseptic (tri-iodomethane) and two drugs with a potent antifibrinolytic activity (tranexamic acid and propyl-hydroxy-benzoic acid) in an absorbable gelatin sponge (Gelfoam) as a vehicle, were histologically assessed with special reference to the parameters related to wound healing."( The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. A preliminary report.
Syrjänen, KJ; Syrjänen, SM, 1981
)
0.26

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" To perform the immediate effect analysis (GPi or zero time), of each mixture either at room or refrigerator temperature, the preparation procedure was similar, although GPR, iodoform, Rifocort and camphorated paramonochlorophenol were stored in the refrigerator and then taken out, dosed and manipulated, and had their immediate effect tested after a 1-week period at storage of 4 degrees C average temperature."( Antimicrobial action of a filling paste used in pulp therapy in primary teeth under different storage conditions.
Ferreira, FV; Friedrich, RS; Guedes-Pinto, AC; Praetzel, JR; Weiss, RN, 2008
)
0.54
"4 μM) were spiked to the raw water samples from Yangshupu and Minhang drinking water treatment plant, certain amounts of CHI3 and IAA were found under pH 7 and the concentrations were strongly correlated with ClO2 dosage and water qualities, however, no TIAA was detected."( Formation of iodinated disinfection by-products during oxidation of iodide-containing waters with chlorine dioxide.
Gao, NY; Hu, CY; Lin, L; Lin, YL; Xu, B; Ye, T; Zhang, TY, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
iodomethanesA halomethane that is methane in which one or more hydrogens has been replaced by iodine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886; AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency33.27160.007215.758889.3584AID1224835; AID624030
15-lipoxygenase, partialHomo sapiens (human)Potency31.62280.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.77280.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency21.13600.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency17.28160.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency1.21750.000221.22318,912.5098AID1259243; AID743042
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
hypothetical protein, conservedTrypanosoma bruceiPotency35.48130.223911.245135.4813AID624173
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.91250.01237.983543.2770AID1346984
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency62.60190.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency6.91670.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency42.43610.001530.607315,848.9004AID1224841; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency24.54120.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.12110.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency53.11890.001019.414170.9645AID588536; AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency58.58730.000723.06741,258.9301AID651777; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.45010.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency52.52030.057821.109761.2679AID1159526; AID1159528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency79.43280.354828.065989.1251AID504847
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency64.86010.000627.21521,122.0200AID651741; AID743202
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency12.58930.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency25.11890.020010.786931.6228AID912
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Nuclear receptor ROR-gammaHomo sapiens (human)Potency16.78550.026622.448266.8242AID651802
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency22.38720.060110.745337.9330AID492961
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (158)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (24.68)18.7374
1990's17 (10.76)18.2507
2000's41 (25.95)29.6817
2010's46 (29.11)24.3611
2020's15 (9.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 72.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index72.86 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index125.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (72.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (9.89%)5.53%
Reviews7 (3.85%)6.00%
Case Studies26 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other131 (71.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]